SEC Form 4 · accession 0001209191-15-047701
PHARMACYCLICS INC · PCYC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Minesh Mehta
Director
Period of report
May 26, 2015
Accepted (ET)
May 28, 2015 · 6:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000949699
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.30 | May 26, 2015 | D | 4,000 | D | — | Sep 10, 2018 | Common Stock | 4,000 | 0 | D |
| Stock Option (Right to Buy)F1 | $14.26 | May 26, 2015 | D | 7,500 | D | — | Dec 15, 2021 | Common Stock | 7,500 | 0 | D |
| Stock Option (Right to Buy)F1 | $28.47 | May 26, 2015 | D | 683 | D | — | Apr 2, 2022 | Common Stock | 683 | 0 | D |
| Stock Option (Right to Buy)F1 | $59.28 | May 26, 2015 | D | 208 | D | — | Jul 2, 2022 | Common Stock | 208 | 0 | D |
| Stock Option (Right to Buy)F1 | $65.56 | May 26, 2015 | D | 267 | D | — | Oct 1, 2022 | Common Stock | 267 | 0 | D |
| Stock Option (Right to Buy)F1 | $49.00 | May 26, 2015 | D | 7,500 | D | — | Nov 9, 2022 | Common Stock | 7,500 | 0 | D |
| Stock Option (Right to Buy)F1 | $61.44 | May 26, 2015 | D | 322 | D | — | Jan 2, 2023 | Common Stock | 322 | 0 | D |
| Stock Option (Right to Buy)F1 | $79.67 | May 26, 2015 | D | 325 | D | — | Apr 1, 2023 | Common Stock | 325 | 0 | D |
| Stock Option (Right to Buy)F1 | $74.48 | May 26, 2015 | D | 3,750 | D | — | May 9, 2023 | Common Stock | 3,750 | 0 | D |
| Stock Option (Right to Buy)F1 | $85.39 | May 26, 2015 | D | 304 | D | — | Jul 1, 2023 | Common Stock | 304 | 0 | D |
| Stock Option (Right to Buy)F1 | $139.89 | May 26, 2015 | D | 184 | D | — | Oct 1, 2023 | Common Stock | 184 | 0 | D |
| Stock Option (Right to Buy)F1 | $108.44 | May 26, 2015 | D | 238 | D | — | Jan 2, 2024 | Common Stock | 238 | 0 | D |
| Stock Option (Right to Buy)F1 | $107.42 | May 26, 2015 | D | 157 | D | — | Apr 1, 2024 | Common Stock | 157 | 0 | D |
| Stock Option (Right to Buy)F1 | $95.08 | May 26, 2015 | D | 3,750 | D | — | May 9, 2024 | Common Stock | 3,750 | 0 | D |
| Stock Option (Right to Buy)F1 | $89.58 | May 26, 2015 | D | 407 | D | — | Jul 1, 2024 | Common Stock | 407 | 0 | D |
| Stock Option (Right to Buy)F1 | $115.80 | May 26, 2015 | D | 314 | D | — | Oct 1, 2024 | Common Stock | 314 | 0 | D |
| Stock Option (Right to Buy)F1 | $124.46 | May 26, 2015 | D | 222 | D | — | Jan 2, 2025 | Common Stock | 222 | 0 | D |
| Stock Option (Right to Buy)F1 | $257.015 | May 26, 2015 | D | 146 | D | — | Apr 7, 2025 | Common Stock | 146 | 0 | D |
Explanation of responses
- F1Pursuant to terms of the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie this option was cancelled in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.